|
||||
| HOME | ABOUT US | PIPELINE | R & D | PUBLICATIONS | PARTNERING | INVESTORS | CAREERS | CONTACT | ||||
|
Publications - Anavex - Relevant scientific publications |
|
|||
|
"Mitochondrial protection in mouse hippocampus against AΒ25-35 toxicity is induced by the novel tetrahydrofuran derivative ANAVEX2-73, a mixed σ1 receptor and cholinergic agonist.”
"Mitochondrial protection is induced by the novel tetrahydrofuran derivative ANAVEX2-73 after ICV injection of oligomeric AΒ25-35 peptide in mice, a nontransgenic Alzheimer's disease model.” Neuroscience 2012, October 13-17, 2012, New Orleans, USA.
"Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1 chaperone protein, in a mouse model of Alzheimer's disease: Analyses of administration schedules and combination studies with donepezil and memantine.” .
"New Adamantane Derivatives with Sigma Affinity and Antiproliferative Activity”.
Medicinal Chemistry 8 (2012) 569-586
“Synthesis, σ1, σ2-receptors binding affinity and antiproliferative action of new C1-substituted adamantanes”.
Bioorganic & Medicinal Chemistry 20 (2012) 3323–3331
“Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease”.
Alzheimer’s Association International Conference, July 16-21, 2011, Paris, France
“The novel tetrahydrofuran derivative ANAVEX2-73 attenuated GSK-3β activation and Tau hyperphosphorylation in a nontransgenic Alzheimer’s disease model in mice”.
Alzheimer’s Association International Conference, July 16-21, 2011, Paris, France
“The sigma-1 receptor chaperone as an inter-organelle signaling modulator”.
Trends Pharmacol Sci. 2010 Sep 23.
“Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma
1 ({sigma}1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative”.
J Psychopharmacol (2010 Sep 9).
“Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative
ANAVEX1-41 against amyloid beta(25-35)-induced toxicity in mice”.
Neuropsychopharmacology (2009 May); 34(6):1552-66.
“The pharmacology of sigma-1 receptors”. Pharmacology & Therapeutics
(2009), journal homepage.
“Anti-amnesic and neuroprotective activities of ANAVEX2-73, a new aminotetrahydrofuran
derivative acting as a mixed muscarinic/sigma-1 ligand, in pharmacological and pathological
models of amnesia”. Poster presentation in The Alzheimer’s Association
2009 International Conference on Alzheimer’s Disease (ICAD), July 11-16 in
Vienna, Austria.
“Antiamnesic and Neuroprotective Effects of the Aminotetrahydrofuran Derivative
ANAVEX1-41 Against Amyloid beta25-35-Induced Toxicity in Mice”. Publication
in Neuropsychopharmacology (December 2008).
“The neuroprotective action of ligands acting at the sigma-1 chaperone protein
involves regulation of the expression of IP3 receptor subtypes and SerCa pumps”.
Poster presentation in Neuroscience 2008, Nov. 15-19 in Washington, DC.
“Neuroprotective effects of activators/agonists of the sigma-1 chaperone protein
against amyloid toxicity in a mouse model”. ICAD (International conference
on Alzheimer’s Disease) (26-31 July 2008), Chicago, USA
“Neuroprotective activity of ANAVEX 1-41, an aminotetrahydrofuran derivative
acting as a mixed muscarinic/sigma-1 ligands, against amyloid beta(25-35) peptide
toxicity in mice”. Poster presentation in Neuroscience 2007, Nov.
3-7 in San Diego, Calif.
“Anti-amnesic and neuroprotective activities of ANAVEX 2-73, a new aminotetrahydrofuran
derivative acting as a mixed muscarinic/sigma-1 ligands, in pharmacological and
pathological models of amnesia”. Poster presentation in Neuroscience
2007, Nov. 3-7 in San Diego, Calif.
“Anavex 7-1037, a novel small synthetic sigma ligand, induces apoptosis in
human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth
in SCID mice.” Poster Presentation in the 15th Euroconference on Apoptosis
& 4th Training course on ’Concepts and Methods in Programmed Cell Death’, October
26-31, 2007 in Portoroz, Slovenia.
“Involvement of the sigma1 (s1) receptor in the antiamnesic, but not antidepressant-like,
effects of the aminotetrahydrofuran derivative ANAVEX 1-41”. British
Journal of Pharmacology (2007).
“Anti-amnesic and neuroprotective potentials of aminotetrahydrofuran derivatives,
mixed muscarinic/sigma1 (s1) ligands, against amyloid beta25-35 peptide toxicity
in mice”. Poster Presentation in the 8e Colloque de la Société
des Neurosciences (May 22-25, 2007), Montpellier, France.
“Involvement of the sigma1 (s1) receptor in the anti-amnesic effects of the
aminotetrahydrofuran derivative AE14”. Poster Presentation in Neuroscience
2006, October 14-18, Atlanta, USA.
“Action mechanism of anticonvulsant and anti-immobility (forced swim) effects
of 3’, 4’-dihydro-N, N-dimethylspiro-[9H-fluorene-9, 2’ (5’H) furane]-3’-methanamine
(AE37F)”. Ann Pharm Fr.; 62(1):49-55 (French) (2004).
“Selective M1 muscarinic agonists: failure of therapeutic strategy against
Alzheimer’s disease or inappropriate tactics?”. Ann Pharm Fr.;
61(3):207-10 Review (French) (2003).
“Mechanism of action of tetrahydro-N, N-dimethyl-5, 5-diphenyl-3-furanemethanamine,
a putative nootropic, anti-epileptic and antidepressant compound”.
Ann Pharm Fr.; 60(6):415-22. (French) (2002).
“Anticonvulsant and forced swim anti-immobility effects of tetrahydro-N, N-dimethyl-2,2-diphenyl-3-furanemethanamine
(AE37): common action mechanism?” Ann Pharm Fr.; 60(2):88-92. Review
(French) (2002).
|
||||
| © 2007-2011 Anavex Life Sciences Corp. - All Rights Reserved. | ||||